Search

Your search keyword '"Piermatteo, L."' showing total 112 results

Search Constraints

Start Over You searched for: Author "Piermatteo, L." Remove constraint Author: "Piermatteo, L."
112 results on '"Piermatteo, L."'

Search Results

1. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort

2. Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies

3. HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV sub-genotypes 1 inducing different inflammatory stimuli

4. Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure

7. for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays

9. An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein

20. In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy

22. Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA

24. Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study

25. The combined usage of accurate virological and serological HBV markers can help to identify HBsAg-negative/anti-HBc-positive patients at higher risk of HBV-reactivation and to optimize prophylaxis duration in oncohematological setting

26. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

27. A close monitoring of virological and immunological hepatitis B markers can improve the diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases

28. The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism

29. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection

30. Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B infection

31. A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

32. Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B

33. Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

34. The levels of middle surface HBVantigen increase in patients with HBV-driven liver cancer despite prolonged virological suppression: implications for a novel marker of HBV-driven hepatocarcinogenesis

37. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

38. An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV-RNA: Implication for disease progression and design of new pharmacological targets

39. Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation.

41. The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification

42. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?

43. Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA

44. Gain of positively charged amino acids at specific positions of HBsAg C-terminus tightly correlates with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain

45. SAT-350 - A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

46. FRI-293 - Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection

Catalog

Books, media, physical & digital resources